New knowledge of the mechanisms of sorafenib resistance in liver cancer

By Yan-jing Zhu, Bo Zheng, Hong-Yang Wang, Lei Chen. Acta Pharmacologica Sinica, 2017

616 citations recorded by the source corpus.

Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the treatment of advanced renal cell carcinoma in 2006, and as a unique target drug for advanced hepatocellular carcinoma (HCC) in 2007. Sorafenib can significantly extend the median survival time of patients but only by 3–5 months. Moreover, it is associated with serious adverse side effects, and drug resistance often develops. Therefore, it is of great importance to explore the mechanisms underlying sorafenib resistance and to develop individualized therapeutic strategies for coping with these problems. Recent studies have revealed that in addition to the primary resistance, several mechanisms are underlying the acquired resistance to sorafenib, such as crosstalk involving PI3K/Akt and JAK-STAT pathways, the activation of hypoxia-inducible pathways, and epithelial-mesenchymal transition. Here, we briefly describe the function of sorafenib, its clinical application, and the molecular mechanisms for drug resistance, especially for HCC patients.

Subfields: Cancer Research, Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2f0e82390bcc2faa1bc6a700b06f5db1d5fa2283

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. David Anwanwan
  2. Shriti Singh
  3. Rajesh Singh
  4. S. K. Singh
  5. Varma Saikam

Citations in the corpus